258 related articles for article (PubMed ID: 35198504)
1. Homocysteine-Lowering Interventions in Chronic Kidney Disease.
Badri S; Vahdat S; Seirafian S; Pourfarzam M; Gholipur-Shahraki T; Ataei S
J Res Pharm Pract; 2021; 10(3):114-124. PubMed ID: 35198504
[TBL] [Abstract][Full Text] [Related]
2. Interventions for lowering plasma homocysteine levels in dialysis patients.
Nigwekar SU; Kang A; Zoungas S; Cass A; Gallagher MP; Kulshrestha S; Navaneethan SD; Perkovic V; Strippoli GF; Jardine MJ
Cochrane Database Syst Rev; 2016 May; 2016(5):CD004683. PubMed ID: 27243372
[TBL] [Abstract][Full Text] [Related]
3. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.
Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P
Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198
[TBL] [Abstract][Full Text] [Related]
4. Role of homocysteine in end-stage renal disease.
Wu CC; Zheng CM; Lin YF; Lo L; Liao MT; Lu KC
Clin Biochem; 2012 Nov; 45(16-17):1286-94. PubMed ID: 22683753
[TBL] [Abstract][Full Text] [Related]
5. The link between homocysteine, folic acid and vitamin B12 in chronic kidney disease.
Angelini A; Cappuccilli ML; Magnoni G; Croci Chiocchini AL; Aiello V; Napoletano A; Iacovella F; Troiano A; Mancini R; Capelli I; Cianciolo G
G Ital Nefrol; 2021 Aug; 38(4):. PubMed ID: 34469084
[TBL] [Abstract][Full Text] [Related]
6. Association of hyperhomocysteinemia and chronic kidney disease in the general population: a systematic review and meta-analysis.
Chen W; Feng J; Ji P; Liu Y; Wan H; Zhang J
BMC Nephrol; 2023 Aug; 24(1):247. PubMed ID: 37612681
[TBL] [Abstract][Full Text] [Related]
7. Homocysteine-lowering interventions for preventing cardiovascular events.
Martí-Carvajal AJ; Solà I; Lathyris D
Cochrane Database Syst Rev; 2015 Jan; 1():CD006612. PubMed ID: 25590290
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation inhibits NADPH oxidase-mediated superoxide anion production in the kidney.
Hwang SY; Siow YL; Au-Yeung KK; House J; O K
Am J Physiol Renal Physiol; 2011 Jan; 300(1):F189-98. PubMed ID: 20980407
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials.
Pan Y; Guo LL; Cai LL; Zhu XJ; Shu JL; Liu XL; Jin HM
Br J Nutr; 2012 Aug; 108(3):400-7. PubMed ID: 22244447
[TBL] [Abstract][Full Text] [Related]
10. Folic Acid and Homocysteine in Chronic Kidney Disease and Cardiovascular Disease Progression: Which Comes First?
Cianciolo G; De Pascalis A; Di Lullo L; Ronco C; Zannini C; La Manna G
Cardiorenal Med; 2017 Oct; 7(4):255-266. PubMed ID: 29118764
[TBL] [Abstract][Full Text] [Related]
11. Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation.
Cetin O; Bekpinar S; Unlucerci Y; Turkmen A; Bayram C; Ulutin T
Clin Nephrol; 2006 Feb; 65(2):97-102. PubMed ID: 16509458
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients.
Nakhoul F; Abassi Z; Plawner M; Khankin E; Ramadan R; Lanir N; Brenner B; Green J
Isr Med Assoc J; 2004 Apr; 6(4):213-7. PubMed ID: 15115259
[TBL] [Abstract][Full Text] [Related]
13. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
[TBL] [Abstract][Full Text] [Related]
14. Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure.
Bernasconi AR; Liste A; Del Pino N; Rosa Diez GJ; Heguilén RM
Nephrology (Carlton); 2006 Apr; 11(2):137-41. PubMed ID: 16669976
[TBL] [Abstract][Full Text] [Related]
15. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.
Righetti M; Serbelloni P; Milani S; Ferrario G
Blood Purif; 2006; 24(4):379-86. PubMed ID: 16755160
[TBL] [Abstract][Full Text] [Related]
16. Folic Acid and Vitamin B12 Administration in CKD, Why Not?
Capelli I; Cianciolo G; Gasperoni L; Zappulo F; Tondolo F; Cappuccilli M; La Manna G
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781775
[TBL] [Abstract][Full Text] [Related]
17. Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications.
Perna AF; Ingrosso D; Castaldo P; De Santo NG; Galletti P; Zappia V
Miner Electrolyte Metab; 1999; 25(1-2):95-9. PubMed ID: 10207268
[TBL] [Abstract][Full Text] [Related]
18. Homocysteine-lowering interventions for preventing cardiovascular events.
Martí-Carvajal AJ; Solà I; Lathyris D; Karakitsiou DE; Simancas-Racines D
Cochrane Database Syst Rev; 2013 Jan; (1):CD006612. PubMed ID: 23440809
[TBL] [Abstract][Full Text] [Related]
19. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M;
Clin Chem Lab Med; 2003 Nov; 41(11):1392-403. PubMed ID: 14656016
[TBL] [Abstract][Full Text] [Related]
20. Homocysteine-lowering therapy in renal disease.
Austen SK; Coombes JS; Fassett RG
Clin Nephrol; 2003 Dec; 60(6):375-85. PubMed ID: 14690253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
